CERRITOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, announced today that Dr. Jeffrey Langsam will assume the role of enterprise Chief Clinical Officer effective May 13th, 2025. The CCO role will oversee therapeutics including pathway and procurement decisions, utilization management, and MSO practice clinical engagement. Dr. Langsam joins TOI from Cigna Healthcare, where he was the Nationa ...

Focused on evaluation of strategic alternatives, with restructuring and closure of the Netherlands operationsEnrollment in LAVA-1266 Phase 1 continues to progressCash, cash equivalents and short-term investments of $66.6 million as of March 31, 2025 expected to fund operations into 2027 UTRECHT, The Netherlands and PHILADELPHIA, May 14, 2025 (GLOBE NEWSWIRE) --  LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on its proprietary Gammabody® bispec ...

TUESDAY, MAY 13, 2025 First Quarter 2025 Financial Results Commercial Update Development Update Pipeline & Discovery Update Nasdaq: EXEL Today's Agenda Introduction First Quarter 2025 Highlights Financial Results & Guidance Q&A Susan Hubbard EVP, Public Affairs and Investor Relations Michael M. Morrissey, Ph.D. President and CEO Chris Senner EVP and CFO PJ Haley EVP, Commercial Amy Peterson, M.D. EVP, Product Development and Medical Affairs and CMO Dana T. Aftab, Ph.D. EVP, Discovery and Translational Resea ...

Fennec Pharmaceuticals (FENC) Q1 2025 Earnings Call May 13, 2025 08:30 AM ET Speaker0 Good morning, ladies and gentlemen, and welcome to FENIC Pharmaceuticals First Quarter twenty twenty five Earnings and Corporate Update Conference Call. At this time, all participants are in a listen only mode. Later, we will conduct a question and answer session and instructions on how to participate will be given at that time. As a reminder, today's conference call is being recorded. Now, I would like to turn the confere ...

Survival observations in mTNBC patients correlated with increased PD-L1 expression Preliminary evidence suggests leronlimab has potential to turn “cold” tumors “hot” VANCOUVER, Washington, May 13, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced new data suggesting a novel mechanism of action of leronlimab for the treatment of solid tumors ...

Core Viewpoint - Affimed N.V. has filed for insolvency proceedings due to insufficient funds to continue operations and has determined that it is overindebted [1][2][3][4]. Group 1: Company Situation - Affimed N.V. is a clinical-stage immuno-oncology company focused on harnessing the innate immune system to combat cancer [5]. - The company has been unable to raise sufficient capital despite ongoing fundraising efforts, leading to substantial doubt about its ability to continue as a going concern [2][3]. - The management board has concluded that both Affimed N.V. and its subsidiary Affimed GmbH are overindebted and must file for insolvency under German law [3][4]. Group 2: Insolvency Proceedings - On May 13, 2025, the management board filed for ordinary insolvency proceedings for both Affimed N.V. and Affimed GmbH with the local court in Mannheim, Germany [4]. - The outcome of the insolvency proceedings remains uncertain, including whether the companies will emerge as going concerns [4]. - The filing for insolvency will lead to the suspension and subsequent delisting of the company's common shares from The Nasdaq Global Market [4].

Core Insights - iTeos Therapeutics and GSK have decided to terminate the belrestotug development program due to the failure to meet established criteria for clinically meaningful improvements in progression-free survival in the GALAXIES Lung-201 trial [1][3] - The GALAXIES Lung-201 trial showed clinically meaningful improvements in the primary endpoint of objective response rate (ORR), but did not meet criteria for the secondary endpoint of progression-free survival [2][3] - iTeos is initiating a targeted review of strategic alternatives to maximize shareholder value following the termination of the belrestotug program [3][4] Company Overview - iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics [5] - The company is headquartered in Watertown, MA, with a research center in Gosselies, Belgium [5] Product Information - Belrestotug is a monoclonal antibody targeting TIGIT, designed to enhance the antitumor response through immune modulation [6]

Coherus BioSciences (CHRS) Q1 2025 Earnings Call May 12, 2025 05:00 PM ET Company Participants Jodi Sievers - Vice President of Investor Relations & Corporate CommunicationsDennis Lanfear - Chairman, President & CEOTheresa Lavallee - Chief Scientific & Development OfficerRosh Dias - Chief Medical OfficerSameer Goregaoker - EVP - CommercialBryan McMichael - CFOKripa Devarakonda - Vice President - Biotechnology Equity ResearchMichael Nedelcovych - Director - Equity Research Conference Call Participants Brian ...

– Strategic transformation to innovative oncology completed in Q2 2025 – – Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion study data in patients with head and neck cancer presented at 2025 AACR Annual Meeting – – Additional CHS-114 Phase 1b studies in 2L gastric cancer and 2L HNSCC ongoing – – Enrollment ongoing in the Phase 2 randomized trial of casdozokitug/toripalimab/bevacizumab in 1L HCC, with first data readout expected in 1H 2026 – – LOQTORZI net revenue was $7.3 million and UDENYCA n ...

Core Insights - Coherus BioSciences has completed its strategic transformation to focus on innovative oncology, with significant advancements in its product pipeline and financial performance [1][3][24] Recent Business Highlights - The company reported positive Phase 1b data for CHS-114, an anti-CCR8 antibody, at the 2025 AACR Annual Meeting, indicating potential for treating various solid tumors [1][3] - LOQTORZI, a next-generation PD-1 inhibitor, generated net revenues of $7.3 million in Q1 2025, with patient demand increasing over 15% compared to Q4 2024 [5][11] - The divestiture of UDENYCA was completed in April 2025, allowing the company to concentrate on its oncology portfolio [3][10] Financial Performance - Net revenue from continuing operations for Q1 2025 was $7.6 million, up from $2.3 million in Q1 2024, primarily driven by higher LOQTORZI sales [11] - The company reported a net loss from continuing operations of $47.4 million, or $(0.41) per share, compared to a loss of $68.0 million, or $(0.60) per share, in the same period last year [17][18] - Cash and cash equivalents decreased to $82.4 million as of March 31, 2025, down from $126.0 million at the end of 2024 [20] Pipeline Development - Ongoing studies for CHS-114 include Phase 1b trials in second-line gastric cancer and head and neck squamous cell carcinoma (HNSCC), with data readouts expected in 2026 [1][13] - Enrollment is ongoing in a Phase 2 trial of casdozokitug in combination with toripalimab and bevacizumab for first-line hepatocellular carcinoma (HCC), with initial data expected in the first half of 2026 [1][13] Strategic Focus - The company aims to maximize LOQTORZI revenues and advance its immuno-oncology candidates, including CHS-114 and casdozokitug, through strategic partnerships and label expansions [3][6][24] - Coherus is positioned to leverage its innovative oncology pipeline to enhance treatment options for cancer patients and drive future growth [3][25]